



arXiv:2308.11537v1 [cs.CL] 22 Aug 2023

Data and text mining

# BELB: a Biomedical Entity Linking Benchmark

Samuele Garda,<sup>1,\*</sup> Leon Weber-Genzel,<sup>2</sup> Robert Martin<sup>1</sup> and Ulf Leser<sup>1,\*</sup>

<sup>1</sup>Computer Science, Humboldt-Universität zu Berlin, Rudower Chaussee 25, 12489, Berlin, Germany and

<sup>2</sup>Center for Information and Language Processing, Ludwig-Maximilians-Universität München, Geschwister-Scholl-Platz 1, 80539, München, Germany

\*Corresponding author. [gardasam@informatik.hu-berlin.de](mailto:gardasam@informatik.hu-berlin.de).

\*Corresponding author. [leser@informatik.hu-berlin.de](mailto:leser@informatik.hu-berlin.de)

FOR PUBLISHER ONLY Received on Date Month Year; revised on Date Month Year; accepted on Date Month Year

## Abstract

**Motivation:** Biomedical entity linking (BEL) is the task of grounding entity mentions to a knowledge base. It plays a vital role in information extraction pipelines for the life sciences literature. We review recent work in the field and find that, as the task is absent from existing benchmarks for biomedical text mining, different studies adopt different experimental setups making comparisons based on published numbers problematic. Furthermore, neural systems are tested primarily on instances linked to the broad coverage knowledge base UMLS, leaving their performance to more specialized ones, e.g. genes or variants, understudied.

**Results:** We therefore developed **BELB**, a **Biomedical Entity Linking Benchmark**, providing access in a unified format to 11 corpora linked to 7 knowledge bases and spanning six entity types: gene, disease, chemical, species, cell line and variant. BELB greatly reduces preprocessing overhead in testing BEL systems on multiple corpora offering a standardized testbed for reproducible experiments. Using BELB we perform an extensive evaluation of six rule-based entity-specific systems and three recent neural approaches leveraging pre-trained language models. Our results reveal a mixed picture showing that neural approaches fail to perform consistently across entity types, highlighting the need of further studies towards entity-agnostic models.

**Availability:** The source code of BELB is available at: <https://github.com/sg-wbi/belb>. The code to reproduce our experiments can be found at: <https://github.com/sg-wbi/belb-exp>.

## 1. Introduction

The task of assigning entity mentions found in biomedical text to a knowledge base (KB) entity is known as Biomedical Entity Linking<sup>1</sup> (BEL). Texts in the biomedical domain are rich in ambiguous expressions, with abbreviation being a prominent example, e.g.: “WSS” can be either “Wrinkly skin syndrome” or “Weaver-Smith syndrome”. BEL resolves such ambiguities and is therefore a crucial component in many downstream applications. For instance it is used to index PubMed (Mork et al., 2013), a primary archive of biomedical literature.

Although several benchmarks have been developed for biomedical text mining, e.g. BLUE (Peng et al., 2019) and BLURB (Gu et al., 2021), BEL is notably absent from all of them. GeneTuring (Hou and Ji, 2023) contains a module to test normalization, but covers only genes and is specific for models built on the GPT-3 architecture. The lack of a standardized evaluation setup translates into a wide variety of approaches: different studies use different combinations of corpus and KB and different evaluation protocols. These differences limit severely direct comparison of results (see Appendix A).

In the biomedical domain different entity types require normalization to different specialized KBs (Wei et al., 2019), e.g. species to NCBI TAXONOMY (Scott, 2012) but genes to NCBI GENE (Brown et al., 2015). Yet, important types such as genes and variants are completely absent from corpora commonly used to evaluate neural BEL approaches (see 2.1.1), which instead only target UMLS. Although adapting neural approaches to

<sup>1</sup> In some studies “entity linking” denotes the joint entity recognition and linking process. We however refer exclusively to the grounding step. The task is also known as Named Entity Normalization and we will use “linking”, “grounding” and “normalizing” interchangeably throughout the text.




Fig. 1: We illustrate the main advantages of BELB. In (a) we see the current stand of experimental setups for biomedical entity linking. Different studies use different (i) preprocessing (I/O routines), (ii) combinations of corpora and KBs and (iii) evaluation protocols, ultimately making published numbers not directly comparable. With BELB (b) researcher have access to (i) uniformly preprocessed corpora and KBs, which can be accessed programmatically and (ii) a standardized evaluation protocol greatly reducing preprocessing overhead and maximizing comparability and reproducibility.

other KBs is possible, it leaves open the question of whether their performance transfers across entity types. Additionally, as corpora are distributed in different formats, developing new BEL approaches (or adapting existing ones to new corpora) requires writing new input-output and quality assurance routines, e.g. to correct wrong mentions boundaries, increasing the overall engineering turnaround.

To facilitate research on BEL, we introduce **BELB**, a **Biomedical Entity Linking Benchmark**. BELB provides access to 11 corpora linked to 7 KBs. All components undergo extensive data cleaning and are converted in a *unified format*, covering six biomedical entities (gene, disease, chemical, species, cell lines and variants). As show in Figure 1, BELB significantly lowers the barrier for research in the field, allowing to (i) train models on corpora in the highest quality possible and (ii) fairly compare them against other approaches with minimal preprocessing overhead (see Appendix B for a simple showcase). Using BELB, we perform an extensive comparison of **six rule-based domain-specific systems and three neural methods**. Our findings show that results of neural approaches do not transfer across entity types, with specialized rule-based systems still being the best option for the gene and disease entity types. We hope that our publicly available benchmark will be adopted by future work allowing to fairly evaluate approaches and accelerate progress towards more robust neural models.

## 2. Materials and methods

In this study we introduce BELB, a benchmark for standardized evaluation of models for BEL. The task is formulated as predicting an entity  $e \in E$  from a KB given a document  $d$  and an entity mention  $m$ , a pair of start and end positions  $\langle m_s, m_e \rangle$  indicating a span in  $d$ . We use BELB to compare rule-based domain-specific systems and state-of-the-art neural approaches. In all experiment we use in-KB gold mentions: each mention has a valid gold KB entity (Röder et al., 2018) and its position in  $d$  is given.

### 2.1. Biomedical Entity Linking Benchmark

We report an overview of the 11 corpora and 7 KBs available in BELB in Table 1 and 2, respectively. Their detailed description can be found in Appendix C. In the following we outline crucial properties of BEL and highlight how they are accounted for in BELB, allowing it to comprehensively analyze and fairly evaluate BEL models.

#### 2.1.1. Specialized knowledge bases

In biomedical information extraction instances of multiple entity types are linked to specialized KBs (Wei et al., 2019). However, recent studies in the NLP community primarily focus on the MedMentions corpus linking to UMLS (Liu et al., 2021; Zhang et al., 2022; Agarwal et al., 2022 inter alia). Additionally, in MedMentions, entity types such as diseases and genes are covered only marginally or not at all, respectively (see Appendix D).

This calls into question how well results obtained in this setting can be transferred for instance to publications in genomics or molecular biology in general. In BELB we cover six entity types

	Documents (train / dev / test)	Annotations (train / dev / test)	0-shot	Stratified
<b>Disease</b>				
NCBI Disease (Doğan et al., 2014)	592 / 100 / 100	5,133 / 787 / 960	150 (15.62%)	185 (19.27%)
BC5CDR (D) (Li et al., 2016)	500 / 500 / 500	4,149 / 4,228 / 4,363	388 (8.89%)	765 (17.53%)
<b>Chemical</b>				
BC5CDR (C)(Li et al., 2016)	500 / 500 / 500	5,148 / 5,298 / 5334	1,038 (19.46%)	415 (7.78%)
NLM-Chem † (Islamaj et al., 2022)	80 / 20 / 50	20,796 / 5,234 / 11514	3,908 (33.94%)	1,534 (13.32%)
<b>Cell line</b>				
BioID ‡ (Arighi et al., 2017)	231 / 59 / 60	3,815 / 1,096 / 864	158 (18.29%)	45 (5.21%)
<b>Species</b>				
Linnaeus † (Martin et al., 2010)	47 / 17 / 31	2,115 / 705 / 1,430	385 (26.92%)	58 (4.06%)
S800 (Pafilis et al., 2013)	437 / 63 / 125	2,557 / 384 / 767	363 (47.33%)	107 (13.95%)
<b>Gene</b>				
GNormPlus (Wei et al., 2015)	279 / 137 / 254	3,015 / 1,203 / 3,222	2,822 (87.59%)	163 (5.06%)
NLM-Gene (Islamaj et al., 2021)	400 / 50 / 100	11,263 / 1,371 / 2,729	1,215 (44.52%)	353 (12.94%)
<b>Variant</b>				
SNP (Thomas et al., 2011)	- / - / 292	- / - / 517	-	-
Osiris v1.2 (Furlong et al., 2008)	- / - / 57	- / - / 261	-	-
tmVar v3 (Wei et al., 2022)	- / - / 214	- / - / 1,018	-	-
<b>UMLS</b>				
MedMentions (Mohan and Li, 2019)	2,635 / 878 / 879	122,178 / 40,864 / 40,143	8,167 (20.34%)	7,945 (19.79%)

**Table 1.** Overview of the corpora available in BELB with their primary characteristics: number of documents, annotations and how many of them are zero-shot (unseen entities) or stratified (seen entity but unseen name). † Full text ‡ Figure captions

	Version	History	Entities	Names	Synonyms	Homonyms (PN)
<b>Disease</b>						
CTD DISEASES (Davis et al., 2023)	monthly †	✗	13,188	88,548	6.71	0.39% (-)
<b>Chemical</b>						
CTD CHEMICALS (Davis et al., 2023)	monthly †	✗	175,663	451,410	2.56	- (-)
<b>Cell line</b>						
CELLOSOURUS (Bairoch, 2018)	-	✓	144,568	251,747	1.74	3.21% (1.22%)
<b>Species</b>						
NCBI TAXONOMY (Scott, 2012)	-	✓	2,491,364	3,783,882	1.51	0.04% (-)
<b>Gene</b>						
NCBI GENE (Brown et al., 2015)	-	✓	42,252,923	105,570,090	2.49	47.37% (8.32%)
GNormPlus subset			703,858	2,455,772	3.48	50.79% (9.13%)
NLM-Gene subset			873,015	2,913,456	3.33	53.61% (9.55%)
<b>Variant</b>						
DBSNP (Sherry et al., 2001)	build 156 †	✓	1,053,854,063	3,119,027,235	2.95	1,557,105,418 (49.92%)
<b>UMLS</b>						
UMLS (Bodenreider, 2004)	2017AA (full)	-	3,464,809	7,938,833	2.29	2.07% (0.16%)

**Table 2.** Overview of the KBs available in BELB according to their entity type. We report the number of entities, synonyms per entity, homonyms and how many of them are the primary name (PN). † No archive of previous versions is provided

(gene, species, disease, chemicals, cell line and variant) represented by 11 corpora linked to 7 specialized KBs (for comparison with previous studies we include UMLS as well). We design a *unified schema* to harmonize all KBs (see Appendix E). This allows to test a model’s ability to preserve performance across multiple pairs of corpus and KB with minimal preprocessing overhead.

### 2.1.2. Unseen entities and synonyms

Corpora typically cover only a small fraction of all entities in a KB. Additionally, biomedical entities present multiple names (*synonyms*), e.g. both “Oculofacial dysplasia” and “Burn-Mckeown Syndrome” are valid names of “MeSH:C563682”. Hence if an entity is in the training set, it does not imply that all its surface forms are included. In BELB we assign a unique identifier

to each mention and provide lists of mentions of (i) unseen entities, i.e. present in the test set but not in the train one (*zero-shot*) and (ii) train entities occurring in the test set but with different (case-insensitive) surface forms (Tutubalina et al., 2020). This allows to easily report a model’s performance in (i) generalizing to new entities and (ii) recognizing known ones appearing in different forms.

### 2.1.3. Homonyms

Discriminating mentions with the same surface form but representing different entities (*homonyms*) by their context is indispensable to BEL. This is because in biomedical KBs the same synonym can be associated to multiple entities. This is especially the case of abbreviations. For instance, as in example (a) in Table

	Example	Entity
a)	Features of ARCL type II overlap with those of Wrinkly skin syndrome ( <b>WSS</b> )	MeSH:C536750
b)	<u>Weaver-Smith syndrome</u> ( <b>WSS</b> ) is a Mendelian disorder of the epigenetic machinery	MeSH:C536687
c)	<b><math>\alpha</math>2microglobulin</b> exacerbates brain damage after stroke in <u>rats</u> .	NCBI GENE:24153
d)	The <u>T67 cell line</u> produced the proteinase inhibitor <b><math>\alpha</math>2microglobulin</b> .	NCBI GENE:2
e)	We identified the novel mutation <b>c.908G&gt;A</b> within exon 8 of the <u>CTSK</u> gene.	rs756250449
f)	The patient was compound heterozygous of the <b>c.908G&gt;A</b> mutation in the <u>SLC17A5</u> gene.	rs1057516601
g)	The GSK650394 inhibitor is used to suppress <u>SGK1</u> expression in <b>PC12 cells</b> .	CVCL_S979
h)	Effects of topography on <u>rat</u> pheochromocytoma cell, <b>PC12 cells</b> , neuritogenesis.	CVCL_0481

**Table 3.** Example of homonym mentions (in **bold**) requiring specific contextual information (underlined) for linking.

3, “WSS” is the abbreviated form of two syndromes and it appears twice in CTD DISEASES. Another example are genes present in multiple species, as in (c), where the string “rats” is essential for correct normalization, as “ $\alpha$ 2microglobulin” could refer either to the human or rat gene. Identifying contextual information can be non-trivial, e.g (c) is the title of a publication, but the text may describe general characteristics of “ $\alpha$ 2microglobulin” introducing textual cues pointing to the human gene. Additionally, this information is not always explicitly expressed and may emerge via other patterns. In example (e) “PC12” denotes a human cell line, whereas in (f) it refers to the rat one. This can be inferred from the capitalized gene mention “SGK1” in (e) which conventionally denotes human genes. By introducing entity types such as genes and variants, BELB allows to probe a model’s ability to (i) identify contextual information and (ii) handle highly ambiguous search spaces (KB).

#### 2.1.4. Scale

As mentioned in Section 2.1.1 studies on neural methods have primarily targeted UMLS, which, as shown in Table 2, is one and three order of magnitude(s) smaller than NCBI GENE and DBSNP, respectively. With its unified format BELB allows to easily test how implementations scale to these large KBs.

#### 2.1.5. Synchronization of KB versions

Entity linking is dynamic by nature: over the years entities in KBs are replaced or become obsolete. For instance, in GNormPlus mentions of “MDS1” are linked to NCBI GENE entity “4197”, which was subsequently replaced by “2122”. As several KBs do not have a versioning system (see Table 2), it is often not possible to retrieve the exact KB used to create a corpus. Failing to account for these changes may introduce a notable amount of noise in measuring performance of high quality systems. BELB offers access to the KB *history* if available, i.e. a table tracking all changes in the entities. In our preprocessing we update all corpora with the KB version at hand and remove mentions linked to obsolete entities. This allows as well to update the predictions of systems shipping with a pre-processed (i.e. non-trivially swappable) KB on corpora created after their release, allowing for fair comparison *over time*.

## 2.2. Evaluated approaches

We use BELB to perform an extensive evaluation of rule-based and neural methods. We now present the selected approaches for evaluation. We stress that we do not re-implement any method (we rely on the original code).

### 2.2.1. Rule-based entity-specific systems

We compare the performance of neural models linking to KBs for which specialized systems have been developed, as these are still the de facto standard in BEL (Wei et al., 2019; Mujeen et al., 2022). Specifically we test the following rule-based methods: GNormPlus (Wei et al., 2015) for genes (NCBI GENE), SR4GN (Wei et al., 2012) for species (NCBI TAXONOMY) and tmVar v3 (Wei et al., 2022) for variants (DBSNP). For UMLS we employ SciSpacy (Neumann et al., 2019). We label them rule-based entity-specific (RBES) as for linking they rely on a mixture of string matching approaches and ad-hoc rules tailored to a specific entity type. For diseases and chemicals, we include in the RBES category two systems which are only *partly* rule-based (stretching our definition), as they better represent the state-of-the-art of disease/chemical-specific models. We use TaggerOne (Leaman and Lu, 2016), a semi-Markov model, for diseases, and opt for the system that won the BioCreative VII NLM-Chem track (Almeida et al., 2022) for chemicals (BC7T2W), which uses both string matching and neural embeddings. To the best of our knowledge there exists no linking approach specific for cell lines. We therefore use a fuzzy string matching approach based on Levenshtein distance (FuzzySearch). For detailed descriptions and information on specific implementations we refer the reader to Appendix G.1. All of these systems do not require re-training as either (i) their normalization component is completely rule-based (SR4GN, tmVar, SciSpacy) or (ii) models trained on the BELB corpora are provided along with the code (GNormPlus, TaggerOne, BC7T2W).

### 2.2.2. Neural systems

We train the following neural models on the train split of each BELB corpus (see Appendix G.2 for training details).

BioSyn (Sung et al., 2020) is a dual encoder architecture. Importantly, BioSyn does not account for context, i.e. it uses only entity mentions. The model is trained via “synonym marginalization”: it learns to maximize the similarity (inner product) between a mention embedding and all the synonyms embeddings of the gold entity. At inference it retrieves the synonyms most similar to the given test mention, i.e. it relies on a lookup from synonym to entity. We prefer BioSyn over SapBERT (Liu et al., 2021) as the latter is primarily a pre-training strategy. GenBioEL (Yuan et al., 2022) is an encoder-decoder model. As input it takes a text with a single mention marked with special tokens. The system is then trained to generate a synonym. At inference it ensures that the prediction is a valid KB synonym by constraining the generation process with a prefix-tree created from all KB synonyms. Similar to BioSyn, this approach represents

KB entities by their synonyms. The authors propose as well “KB-Guided Pre-training”, i.e. a method based on prompting to pre-train GenBioEL on the KB, which we however do not deploy. This is because (i) it would introduce an advantage over other neural methods and (ii) it is too computationally expensive to run for each KB.

**arboEL** (Agarwal et al., 2022) is a dual encoder as well. The authors propose to construct k-nearest neighbor graphs over mention and entity clusters. Using a pruning algorithm they then generate directed minimum spanning trees rooted at entity nodes, and use the edges as positive examples for training. At inference they use the entity present in the mention’s cluster. Notably, arboEL learns *entity embeddings*, encoded as a concatenated list of synonyms. The authors use as well a cross-encoder (Wu et al., 2020), i.e. using the top-64 entities retrieved by a trained arboEL as hard negatives (training) and as linking candidates (inference) for a second reranking model. In our experiments we do not make use of this extension as it is not strictly part of the arboEL algorithm.

### 2.3. Evaluation protocol

We now describe in detail the evaluation protocol which we followed in our experiments. For all systems we report the *mention-level* recall@1 (accuracy), since RBES approaches generate only a single candidate.

#### 2.3.1. Synonym as entity proxy

Approaches using strings as proxies for entities (BioSyn, GenBioEL) cannot meaningfully resolve ambiguous mentions. That is, for a mention of rat “ $\alpha$ 2microglobulin”, they would return a list containing *both* NCBI GENE “2” (human) and “24153” (rat). Sung et al. (2020) introduced a *lenient* evaluation, which considers a prediction correct if any of the returned entities matches the gold one. As reported by Zhang et al. (2022), this largely overestimates performance. Following their suggestion, we opt for a *standard* evaluation, which randomly samples one prediction from the returned list. However, as one of the aims of BEL is direct deployment in extraction pipelines, e.g. for constructing gene networks (Lehmann et al., 2015), we also include a *strict* evaluation in which all such cases, i.e. multiple predictions, are considered incorrect.

#### 2.3.2. Disentangling recognition and linking

Some RBES systems (GNormPlus, SR4GN, TaggerOne, tmVar) perform entity recognition and linking jointly (see Appendix G.1). Due to false negatives in the NER step we cannot obtain their results on the full test set. To ensure that we are measuring the performance on the same instances for all methods, for corpora whose reference RBES system is a joint approach, we use only the test mentions which are correctly identified during entity recognition. For instance, for **NLM-Gene** we use only 73% of the test mentions, i.e. those correctly recognized by GNormPlus (see Table 13 for other corpora). As correct recognition correlates with correct normalization, our evaluation protocol probably introduces a bias towards RBES systems (see Section 4).

#### 2.3.3. Multiple gold entities

Mentions in biomedical corpora can provide multiple normalizations. Common instances are *composite mentions*, e.g. “breast and

squamous cell neoplasms” and ambiguous ones, e.g. “Toll-like receptor” (“Toll-like receptor 2”, “4” and “9”). Whether these cases are logical AND or OR is not always specified in the annotation guidelines. We opt for the more lenient OR interpretation and consider a prediction correct if it matches one of the gold entities.

## 3. Results

Entity type	RBES	BioSyn	GenBioEL	arboEL
Corpus				
<b>Disease</b>	0.94	0.87	0.90	0.87
NCBI Disease	0.94	0.83	0.89	0.86
BC5CDR (D)	0.94	0.88	0.92	0.88
<b>Chemical</b>	0.72	0.72	0.81	0.77
BC5CDR (C)	0.82	0.85	0.95	0.88
NLM-Chem	0.67	0.67	0.75	0.72
<b>Cell line</b>				
BioID	0.82	0.82	0.96	0.95
<b>Species</b>	0.97	0.91	0.85	0.76
Linnaeus	0.99	0.93	0.81	0.74
S800	0.93	0.88	0.93	0.79
<b>Gene</b>	0.82	-	0.17	0.30
GNormPlus	0.87	OOM	0.21	0.36
NLM-Gene	0.76	OOM	0.13	0.23
<b>Variant</b>	0.91	-	-	-
SNP†	0.94	-	-	-
Osiris v1.2	0.91	-	-	-
tmVar v3	0.88	-	-	-
<b>UMLS</b>				
MedMentions	0.58	OOM	0.57	0.69

**Table 4.** Performance of all baselines on BELB (test set). All scores are *mention-level* recall@1. OOM: out-of-memory (>200GB)

Table 4 reports the results of neural models and entity-specific models grouped under the RBES category. For results with strict evaluation (Section 2.3.1) and on the full test sets (Section 2.3.2) please see Table 14 and 15, respectively. We observe that performance of neural models varies significantly across entity types, with disease and genes corpora incurring the most significant drop.

**Homonyms** Beside the implicit bias towards RBES approaches (see Section 2.3.2), we hypothesize that an important factor at play are homonyms. RBES systems use ad-hoc components to handle these challenging cases. For instance GNormPlus directly integrates Ab3P (Sohn et al., 2008), a widely adopted abbreviation resolution tool, and SR4GN, which is specifically developed for cross-species gene normalization. Neural models lack these components, and synonym-based approaches are significantly impacted by random selection in case of homonyms. In table 5 we show that if we resolve abbreviation with Ab3P there is a notable improvement in performance for diseases. Similarly, if we use a lenient evaluation (see Section 2.3.1), GenBioEL is almost on par with GNormPlus on genes. In contrast, abbreviation resolution

	NCBI Disease	GNormPlus
RBES	0.94	0.87
BioSyn	0.83	OOM
+ abbr. res.	0.88 (+0.5%)	-
+ lenient eval.	0.88 (+0.5%)	-
GenBioEL	0.89	0.21
+ abbr. res.	0.91 (+0.2%)	0.20 (-0.1%)
+ lenient eval.	0.90 (+0.1%)	0.86 (+65%)
arboEL	0.86	0.36
+ abbr. res.	0.86 (-)	0.36 (-)
+ lenient eval.	-	-

**Table 5.** Relative improvement of neural models with resolved abbreviations and a lenient evaluation in case of multiple *predicted* entities. OOM: out-of-memory (>200GB)

has no impact on arboEL. We argue that this is due to the fact that arboEL uses entity embeddings, which benefit less by long forms mentions. Secondly, as entity embeddings require to learn a compressed entity representation, arboEL is affected by the limited size of the corpora. This is supported by results on MedMentions, which is one order of magnitude larger than other BELB corpora, where arboEL is confirmed the state-of-the-art approach.

	Unseen entities	Unseen synonyms
RBES	0.65	0.40
GenBioEL	0.50	0.48
arboEL	0.45	0.50

**Table 6.** Results on unseen entities and synonyms (*mention-level recall@1*).

**Unseen entities and synonyms** In Table 6 we see that neural approaches are outperformed by RBES systems on mentions of unseen entities while we the opposite happens with unseen synonyms of train entities. This can be explained by the fact that as string-matching approaches have direct access to the KB they are better suited for the zero-shot cases. If training data is available, neural representation are superior instead, as they can leverage representations learned from context.

**Scale** Neural models implementations fail to scale to large KBs such as NCBI GENE or dbSNP. In our experiments resorted to use the NCBI GENE subset determined by the species of the entities found in the gene corpora (see Table 2). This reflects a common real-world use case scenario, since often only a specific subset of species is relevant for linking (e.g. human and mouse). For dbSNP we are not aware of a valid criterion to subset it and we are therefore unable to run neural models on variants corpora.

**Synchronization of KB version** Corpora are only sparsely affected by changes in entities. However, if they are not handled properly, in BC5CDR (C) and Linnaeus (the most affected corpora in BELB), even if evaluating a perfect system, we would register an error rate of 4.56% and 3.57% respectively (see Appendix F).

## 4. Discussion

We strived to include in BELB as many corpora and KBs as possible, prioritizing those which are most commonly used by

the community. We leave as further improvement the expansion to other important research directions as applications to clinical notes (Luo et al., 2020) and other languages as Spanish (Miranda-Escalada et al., 2022) and German (Kittner et al., 2021).

Our evaluation showed that neural approaches fail to perform consistently across all BELB instances, especially on genes, where RBES approaches are still far superior. However, as reported in Section 2.3.2, our evaluation protocol introduces a bias towards RBES systems by considering exclusively the test mentions they correctly identify. Nonetheless, we believe that this is the best approximation to compare results across all methods. We note as well the lack of hyperparameter exploration in neural models. Due to the high computational resources necessary we rely on the default ones reported by the authors. It is therefore likely that optimizing them may result in better numbers. Further improvements may be possible by pre-training on the KB (Liu et al., 2021; Yuan et al., 2022) and refining candidates with a cross-encoder (Agarwal et al., 2022). RBES systems are advantaged by the use of ad-hoc components to handle homonyms. In Table 5 we show that introducing similar approaches for neural models could significantly improve their performance. However, as the neural paradigm is based on learning task-related capabilities from data (Bengio et al., 2013), we believe that future studies should nevertheless continue to investigate entity-agnostic models, rather than falling back to custom-made hand-crafted heuristics.

## 5. Conclusion

We presented BELB, a benchmark to standardize experimental setups for biomedical entity linking. We conducted an extensive evaluation of rule-based entity-specific systems and recent neural approaches. We find that the first are still the state-of-the-art on entity-types not explored by neural approaches, namely genes and variants. We hope that BELB will encourage future studies to compare approaches with a common testbed and to address current limitations of neural approaches.

## Acknowledgements

Samuele Garda and Robert Martin are supported by the *Deutsche Forschungsgemeinschaft* as part of the research unit “Beyond the Exome”.

## References

- D. Agarwal, R. Angell, N. Monath, and A. McCallum. Entity linking via explicit mention-mention coreference modeling. In *Proceedings of the 2022 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies*, pages 4644–4658. Association for Computational Linguistics, 2022. doi: 10.18653/v1/2022.naacl-main.343.
- T. Almeida, R. Antunes, J. a. F. Silva, J. a. R. Almeida, and S. Matos. Chemical identification and indexing in pubmed full-text articles using deep learning and heuristics. *Database*, 2022, 7 2022. doi: 10.1093/database/baac047.
- R. Angell, N. Monath, S. Mohan, N. Yadav, and A. McCallum. Clustering-based inference for biomedical entity linking. In *Proceedings of the 2021 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies*, page 2598–2608. Association

- for Computational Linguistics, 2021. doi: 10.18653/v1/2021.naacl-main.205.
- C. Arighi, L. Hirschman, T. Lemberger, S. Bayer, R. Liechti, D. Comeau, and C. Wu. Bio-id track overview. In *BioCreative VI Challenge Evaluation Workshop*, volume 482, page 376, 2017.
- A. Bairoch. The cellosaurus, a cell-line knowledge resource. *Journal of Biomolecular Techniques : JBT*, 29:25–38, 7 2018. doi: 10.7171/jbt.18-2902-002.
- Y. Bengio, A. Courville, and P. Vincent. Representation learning: A review and new perspectives. *IEEE transactions on pattern analysis and machine intelligence*, 35(8):1798–1828, 2013.
- O. Bodenreider. The Unified Medical Language System (UMLS): integrating biomedical terminology. *Nucleic Acids Research*, 32(suppl\_1):D267–D270, 2004. ISSN 0305-1048. doi: 10.1093/nar/gkh061.
- G. R. Brown, V. Hem, K. S. Katz, M. Ovetsky, C. Wallin, O. Ermolaeva, I. Tolstoy, T. Tatusova, K. D. Pruitt, D. R. Maglott, and T. D. Murphy. Gene: a gene-centered information resource at ncbi. *Nucleic Acids Research*, 43(D1):D36–D42, 2015. ISSN 0305-1048. doi: 10.1093/nar/gku1055.
- L. Chen, G. Varoquaux, and F. M. Suchanek. A lightweight neural model for biomedical entity linking. *Proceedings of the AAAI Conference on Artificial Intelligence*, 35(14):12657–12665, 2021. ISSN 2374-3468. URL <https://ojs.aaai.org/index.php/AAAI/article/view/17499>.
- A. P. Davis, T. C. Wieggers, R. J. Johnson, D. Sciaky, J. Wieggers, and C. J. Mattingly. Comparative toxicogenomics database (ctd): update 2023. *Nucleic Acids Research*, 51:D1257–D1262, 1 2023. doi: 10.1093/nar/gkac833.
- R. I. Doğan, R. Leaman, and Z. Lu. Ncbi disease corpus: A resource for disease name recognition and concept normalization. *Journal of Biomedical Informatics*, 47:1–10, 2014. ISSN 1532-0464. doi: 10.1016/j.jbi.2013.12.006.
- L. I. Furlong, H. Dach, M. Hofmann-Apitius, and F. Sanz. Osirisv1.2: A named entity recognition system for sequence variants of genes in biomedical literature. *BMC Bioinformatics*, 9, 12 2008. doi: 10.1186/1471-2105-9-84.
- Y. Gu, R. Tinn, H. Cheng, M. Lucas, N. Usuyama, X. Liu, T. Naumann, J. Gao, and H. Poon. Domain-Specific Language Model Pretraining for Biomedical Natural Language Processing. *ACM Transactions on Computing for Healthcare*, 3(1):2:1–2:23, 2021. ISSN 2691-1957. doi: 10.1145/3458754.
- A. Hamosh, A. F. Scott, J. S. Amberger, C. A. Bocchini, and V. A. McKusick. Online mendelian inheritance in man (omim), a knowledgebase of human genes and genetic disorders. *Nucleic acids research*, 33(suppl\_1):D514–D517, 2005.
- W. Hou and Z. Ji. Geneturing tests gpt models in genomics, 3 2023.
- R. Islamaj, C.-H. Wei, D. Cissel, N. Miliaras, O. Printseva, O. Rodionov, K. Sekiya, J. Ward, and Z. Lu. Nlm-gene, a richly annotated gold standard dataset for gene entities that addresses ambiguity and multi-species gene recognition. *Journal of biomedical informatics*, 118:103779, 2021. ISSN 1532-0480. doi: 10.1016/j.jbi.2021.103779.
- R. Islamaj, R. Leaman, D. Cissel, C. Coss, J. Denicola, C. Fisher, R. Guzman, P. G. Kochar, N. Miliaras, Z. Punske, K. Sekiya, D. Trinh, D. Whitman, S. Schmidt, and Z. Lu. Nlm-chem-bc7: manually annotated full-text resources for chemical entity annotation and indexing in biomedical articles. *Database*, 2022, 12 2022. doi: 10.1093/database/baac102.
- M. Kittner, M. Lamping, D. T. Rieke, J. Götze, B. Bajwa, I. Jelas, G. Rüter, H. Hautow, M. Sängler, M. Habibi, M. Zettwitz, T. d. Bortoli, L. Ostermann, J. Ševa, J. Starlinger, O. Kohlbacher, N. P. Malek, U. Keilholz, and U. Leser. Annotation and initial evaluation of a large annotated german oncological corpus. *JAMIA Open*, 4(2), 04 2021. ISSN 2574-2531. doi: 10.1093/jamiaopen/ooab025. ooab025.
- T. Lai, H. Ji, and C. Zhai. Bert might be overkill: A tiny but effective biomedical entity linker based on residual convolutional neural networks. In *Findings of the Association for Computational Linguistics: EMNLP 2021*, page 1631–1639. Association for Computational Linguistics, 2021.
- R. Leaman and Z. Lu. Taggerone: joint named entity recognition and normalization with semi-markov models. *Bioinformatics*, 32(18):2839–2846, 2016. ISSN 1367-4803. doi: 10.1093/bioinformatics/btw343.
- J. Lee, W. Yoon, S. Kim, D. Kim, S. Kim, C. H. So, and J. Kang. Biobert: a pre-trained biomedical language representation model for biomedical text mining. *Bioinformatics*, 36(4):1234–1240, 2020.
- R. Lehmann, L. Childs, P. Thomas, M. Abreu, L. Fuhr, H. Herzel, U. Leser, and A. Relógio. Assembly of a comprehensive regulatory network for the mammalian circadian clock: A bioinformatics approach. *PLOS ONE*, 10:e0126283, 5 2015. doi: 10.1371/journal.pone.0126283.
- M. Lewis, Y. Liu, N. Goyal, M. Ghazvininejad, A. Mohamed, O. Levy, V. Stoyanov, and L. Zettlemoyer. Bart: Denoising sequence-to-sequence pre-training for natural language generation, translation, and comprehension. *Proceedings of the 58th Annual Meeting of the Association for Computational Linguistics*, 7 2020. doi: 10.18653/v1/2020.acl-main.703.
- J. Li, Y. Sun, R. J. Johnson, D. Sciaky, C.-H. Wei, R. Leaman, A. P. Davis, C. J. Mattingly, T. C. Wieggers, and Z. Lu. Biocreative v cdr task corpus: a resource for chemical disease relation extraction. *Database*, 2016(baw068), 2016. ISSN 1758-0463. doi: 10.1093/database/baw068.
- C. E. Lipscomb. Medical subject headings (mesh). *Bulletin of the Medical Library Association*, 88(3):265, 2000.
- F. Liu, E. Shareghi, Z. Meng, M. Basaldella, and N. Collier. Self-alignment pretraining for biomedical entity representations. In *Proceedings of the 2021 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies*, page 4228–4238. Association for Computational Linguistics, 2021. doi: 10.18653/v1/2021.naacl-main.334.
- Y.-F. Luo, S. Henry, Y. Wang, F. Shen, O. Uzuner, and A. Rumshisky. The 2019 n2c2/umass lowell shared task on clinical concept normalization. *Journal of the American Medical Informatics Association*, 27:1529–e1, 10 2020. doi: 10.1093/jamia/ocaa106.
- G. Martin, N. Goran, and B. Casey M. Linnaeus: A species name identification system for biomedical literature. *BMC Bioinformatics*, 11, 2010. ISSN 1471-2105. doi: 10.1186/1471-2105-11-85.
- A. Miranda-Escalada, L. Gascó, S. Lima-López, E. Farré-Maduell, D. Estrada, A. Nentidis, A. Krithara, G. Katsimpras, G. Paliouras, and M. Krallinger. Overview of distemist at biosq: Automatic detection and normalization of diseases from clinical texts: results, methods, evaluation and multilingual resources. *Working Notes of Conference and Labs of the Evaluation (CLEF) Forum. CEUR Workshop Proceedings*,

- 2022.
- S. Mohan and D. Li. Medmentions: A large biomedical corpus annotated with umls concepts. In *In Proceedings of the 2019 Conference on Automated Knowledge Base Construction (AKBC 2019)*, 2019.
- A. A. Morgan, Z. Lu, X. Wang, A. M. Cohen, J. Fluck, P. Ruch, A. Divoli, K. Fundel, R. Leaman, J. Hakenberg, C. Sun, H.-h. Liu, R. Torres, M. Krauthammer, W. W. Lau, H. Liu, C.-N. Hsu, M. Schuemie, K. B. Cohen, and L. Hirschman. Overview of biocreative ii gene normalization. *Genome Biology*, 9:S3, 2008. doi: 10.1186/gb-2008-9-s2-s3.
- J. G. Mork, A. J. J. Yepes, and A. R. Aronson. The.nlm medical text indexer system for indexing biomedical literature. 2013.
- S. Mujeen, J. Minbyul, C. Yonghwa, K. Donghyeon, L. Jinhyuk, and K. Jaewoo. Bern2: an advanced neural biomedical named entity recognition and normalization tool. *Bioinformatics*, 38, 2022. ISSN 1367-4803. doi: 10.1093/bioinformatics/btac598.
- M. Neumann, D. King, I. Beltagy, and W. Ammar. Scispacy: Fast and robust models for biomedical natural language processing. In *Proceedings of the 18th BioNLP Workshop and Shared Task*, page 319–327. Association for Computational Linguistics, 2019. doi: 10.18653/v1/W19-5034.
- E. Pafilis, S. P. Frankild, L. Fanini, S. Faulwetter, C. Pavloudi, A. Vasileiadou, C. Arvanitidis, and L. J. Jensen. The species and organisms resources for fast and accurate identification of taxonomic names in text. *PLOS ONE*, 8(6):e65390, 2013. ISSN 1932-6203. doi: 10.1371/journal.pone.0065390.
- Y. Peng, S. Yan, and Z. Lu. Transfer Learning in Biomedical Natural Language Processing : An Evaluation of BERT and ELMo on Ten Benchmarking Datasets. In *Proceedings of the 18th BioNLP Workshop and Shared Task*, pages 58–65. Association for Computational Linguistics, 2019. doi: 10.18653/v1/W19-5006.
- M. Röder, R. Usbeck, and A.-C. Ngonga Ngomo. Gerbil – benchmarking named entity recognition and linking consistently. *Semantic Web*, 9:605–625, 8 2018. doi: 10.3233/sw-170286.
- A. S. Schwartz and M. A. Hearst. A simple algorithm for identifying abbreviation definitions in biomedical text. In *Biocomputing 2003*, pages 451–462. World Scientific, 2002.
- F. Scott. The ncbi taxonomy database. *Nucleic Acids Research*, 40:D136–D143, 1 2012. ISSN 0305-1048. doi: 10.1093/nar/gkr1178.
- S. T. Sherry, M.-H. Ward, M. Kholodov, J. Baker, L. Phan, E. M. Smigielski, and K. Sirotkin. dbsnp: the ncbi database of genetic variation. *Nucleic Acids Research*, 29(1):308–311, 2001. ISSN 0305-1048. doi: 10.1093/nar/29.1.308.
- S. Sohn, D. C. Comeau, W. Kim, and W. J. Wilbur. Abbreviation definition identification based on automatic precision estimates. *BMC Bioinformatics*, 9, 12 2008. doi: 10.1186/1471-2105-9-402.
- M. Sung, H. Jeon, J. Lee, and J. Kang. Biomedical Entity Representations with Synonym Marginalization . In *Proceedings of the 58th Annual Meeting of the Association for Computational Linguistics*, pages 3641–3650. Association for Computational Linguistics, 2020. doi: 10.18653/v1/2020.acl-main.335.
- P. Thomas, T. Rocktäschel, J. Hakenberg, Y. Lichtblau, and U. Leser. Seth detects and normalizes genetic variants in text. *Bioinformatics*, 32(18):2883–2885, 2016. ISSN 1367-4803. doi: 10.1093/bioinformatics/btw234.
- P. E. Thomas, R. Klinger, L. I. Furlong, M. Hofmann-Apitius, and C. M. Friedrich. Challenges in the association of human single nucleotide polymorphism mentions with unique database identifiers. *BMC Bioinformatics*, 12, 12 2011. doi: 10.1186/1471-2105-12-s4-s4.
- E. Tutubalina, A. Kadurin, and Z. Miftahutdinov. Fair evaluation in concept normalization: a large-scale comparative analysis for bert-based models. In *Proceedings of the 28th International Conference on Computational Linguistics*, page 6710–6716. International Committee on Computational Linguistics, 2020. doi: 10.18653/v1/2020.coling-main.588.
- M. Varma, L. Orr, S. Wu, M. Leszczynski, X. Ling, and C. Ré. Cross-domain data integration for named entity disambiguation in biomedical text. *Findings of the Association for Computational Linguistics: EMNLP 2021*, 11 2021. doi: 10.18653/v1/2021.findings-emnlp.388.
- C.-H. Wei, H.-Y. Kao, and Z. Lu. SR4GN: a species recognition software tool for gene normalization. *PLoS ONE*, 7(6):e38460, 2012. doi: 10.1371/journal.pone.0038460.
- C.-H. Wei, H.-Y. Kao, and Z. Lu. Gnormplus: An integrative approach for tagging genes, gene families, and protein domains. *BioMed Research International*, 2015:e918710, 2015. ISSN 2314-6133. doi: 10.1155/2015/918710.
- C.-H. Wei, A. Allot, R. Leaman, and Z. Lu. Pubtator central: automated concept annotation for biomedical full text articles. *Nucleic Acids Research*, 47(W1):W587–W593, 2019. ISSN 0305-1048. doi: 10.1093/nar/gkz389.
- C.-H. Wei, A. Allot, K. Riehle, A. Milosavljevic, and Z. Lu. tmVar 3.0: an improved variant concept recognition and normalization tool. *Bioinformatics*, 38(18):4449–4451, 2022. ISSN 1367-4803. doi: 10.1093/bioinformatics/btac537.
- L. Wu, F. Petroni, M. Josifoski, S. Riedel, and L. Zettlemoyer. Scalable zero-shot entity linking with dense entity retrieval. In *Proceedings of the 2020 Conference on Empirical Methods in Natural Language Processing (EMNLP)*, page 6397–6407. Association for Computational Linguistics, 2020. doi: 10.18653/v1/2020.emnlp-main.519.
- H. Yuan, Z. Yuan, and S. Yu. Generative biomedical entity linking via knowledge base-guided pre-training and synonyms-aware fine-tuning. In *Proceedings of the 2022 Conference of the North American Chapter of the Association for Computational Linguistics: Human Language Technologies*. Association for Computational Linguistics, 2022. doi: 10.18653/v1/2022.naacl-main.296.
- S. Zhang, H. Cheng, S. Vashishth, C. Wong, J. Xiao, X. Liu, T. Naumann, J. Gao, and H. Poon. Knowledge-rich self-supervision for biomedical entity linking. In *Findings of the Association for Computational Linguistics: EMNLP 2022*, pages 868–880. Association for Computational Linguistics, 2022.

## A. Neural biomedical entity linking

Studies in BEL have converged to using primarily three corpora: NCBI Disease (Doğan et al., 2014), BC5CDR (Li et al., 2016) and MedMentions (Mohan and Li, 2019). However, as shown in Table 7, where we report a summary of recent approaches, experimental setups differ importantly in terms of the corpora and KBs used, making comparison based solely on published numbers problematic. For instance, in BioSyn the BC5CDR corpus is divided into two, distinguishing between chemical and disease entities, and linked to the CTD vocabularies, while GenBioEL reports results on the entire corpus linking to MeSH,

Model Abbr. res. / Pre-train / Lenient eval.	BC5CDR (Disease / Chemical)	NCBI Disease	MedMentions
BioSyn (Sung et al., 2020) Sohn et al. (2008) / - / yes	93.2 (CTD Diseases) / 96.6 (CTD Chemicals)	91.1 (CTD Diseases)	-
SapBERT (Liu et al., 2021) Sohn et al. (2008) / KB / yes	93.2 (CTD Diseases) / 96.5 (CTD Chemicals)	92.3 (CTD Diseases)	50.4
BertOverkill (Lai et al., 2021) Sohn et al. (2008) / - / yes	93.2 (CTD Diseases) / 96.9 (CTD Chemicals)	92.2 (CTD Diseases)	55.0
LightweightBEL (Chen et al., 2021) Sohn et al. (2008) / - / no	-	89.59 (CTD Diseases)	-
ClusteringInference (Angell et al., 2021) Sohn et al. (2008) / - / no	91.3 (UMLS) † ‡	-	74.1 ‡
MedWiki (Varma et al., 2021) Schwartz and Hearst (2002) / Wikipedia, PubMed / no	91.5 (UMLS) † ‡	-	74.6 ‡
KRISSBERT (Zhang et al., 2022) - / PubMed / no	90.7 (UMLS) / 96.9 (UMLS) ‡	89.9 (UMLS) ‡	70.6 ‡
GenBioEL (Yuan et al., 2022) Sohn et al. (2008) / KB / yes	92.6 (MeSH) † ◇	91.6 (CTD Diseases) ◇	-
arboEL (Agarwal et al., 2022) - / - / no	-	-	72.31

**Table 7.** Overview of experimental designs adopted by recent neural approaches for biomedical entity linking. We highlight with a color all cells reporting results which can be compared directly, i.e.: same corpus and knowledge base, abbreviation resolution (Abbr. Res.), pre-training (if any) and evaluation protocol. † No distinction between disease and chemical annotations ‡ Reranking model ◇ Ablation study without pre-training

preventig direct comparison. Notably, neural approaches rely on different pre-training strategies with different data sources, making the training signal vary significantly across approaches. This ultimately hinders estimating the difference in performance stemming purely from algorithmic differences. For instance MedWiki outperforms KRISSBERT on MedMentions, but as it is pre-trained on a larger pool of documents, it unclear whether this is due to differences in pre-training or model architecture. Similarly, it is not possible to directly estimate the impact of using abbreviation resolution in the reported performance. Finally, studies differ in the type of evaluation used, with some models deploying a lenient evaluation (see Section 2.3.1) further hindering direct comparison even if the corpus and the KB are the same.

## B. Showcase

In Listing 1 we show that with BELB in less than 30 lines of code it is possible to test a simple exact-match approach on all its available pairs of corpus and knowledge base.

## C. Corpora and Knowledge Bases

In this section we describe in detail the corpora and knowledge bases contained in BELB, grouped by their entity type:

**Gene** For genes, in contrast to previous approaches (Tutubalina et al., 2020), we use GNormPlus (Wei et al., 2015) instead of the BioCreative II Gene Normalization (BC2GN) corpus (Morgan et al., 2008). This is because BC2GN (i) is limited to human genes and (ii) it provides identifier annotations only at the *document level*. GNormPlus consists of two corpora re-annotated at the *mention level*, namely: BC2GN and the Gene Indexing

**Listing 1** Example code to test an exact-match approach on BELB.

```

1 from collections import defaultdict(list)
2 from sqlalchemy import select
3 from belb import (AutoBelbKb, AutoBelbCorpus,
4                  CORPUS_TO_KB, Tables)
5
6 from belb.resources import Corpora, Kbs
7
8 for corpus in Corpora:
9     corpus = AutoBelbCorpus.from_name(corpus.name)
10
11     kb = AutoBelbKb.from_name(CORPUS_TO_KB[corpus.name])
12
13     table = kb.schema.get(Tables.KB)
14     query = select(table.c.entity, table.c.name)
15
16     name_to_entity = defaultdict(list)
17     with kb as handle:
18         for row in handle.query(query):
19             synonym = row["name"].lower()
20             name_to_entity[synonym].append(row["entity"])
21
22     for document in corpus["test"]:
23         for a in document.annotations:
24             name_to_entity.get(a.text.lower(), -1)

```

Assistant (GIA) test collection<sup>2</sup>. We devote the GIA test collection as development split since GNormPlus (corpus) does not provide one. We include as well NLM-Gene (Islamaj et al., 2021), which covers ambiguous gene names by including more species. As it

<sup>2</sup> <https://ii.nlm.nih.gov/TestCollections/>

	Website (link)	Lincense
<b>Corpora</b>		
GNormPlus	<a href="https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/gnormplus/">https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/gnormplus/</a>	Public domain
NLM-Gene	<a href="https://zenodo.org/record/5089049">https://zenodo.org/record/5089049</a>	CC0 1.0
NCBI Disease	<a href="https://www.ncbi.nlm.nih.gov/CBBresearch/Dogan/DISEASE/">https://www.ncbi.nlm.nih.gov/CBBresearch/Dogan/DISEASE/</a>	Public domain
BC5CDR	<a href="https://biocreative.bioinformatics.udel.edu/tasks/biocreative-v/track-3-cdr/">https://biocreative.bioinformatics.udel.edu/tasks/biocreative-v/track-3-cdr/</a>	Public domain
NLM-Chem	<a href="https://biocreative.bioinformatics.udel.edu/tasks/biocreative-vii/track-2/">https://biocreative.bioinformatics.udel.edu/tasks/biocreative-vii/track-2/</a>	CC0 1.0
Linnaeus	<a href="https://linnaeus.sourceforge.net/">https://linnaeus.sourceforge.net/</a>	N/A
S800	<a href="https://species.jensenlab.org/">https://species.jensenlab.org/</a>	N/A
BioID	<a href="https://biocreative.bioinformatics.udel.edu/tasks/biocreative-vi/track-1/">https://biocreative.bioinformatics.udel.edu/tasks/biocreative-vi/track-1/</a>	N/A
MedMentions	<a href="https://github.com/chanzuckerberg/MedMentions">https://github.com/chanzuckerberg/MedMentions</a>	CC0 1.0
SNP	<a href="http://www.scai.fraunhofer.de/snp-normalization-corpus.html">http://www.scai.fraunhofer.de/snp-normalization-corpus.html</a>	N/A ‡
Osiris v1.2	<a href="http://dx.doi.org/10.1186/1471-2105-9-84">http://dx.doi.org/10.1186/1471-2105-9-84</a> †	CC BY 3.0
tmVar v3	<a href="https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/tmvar/">https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/tmvar/</a>	Public domain
<b>Knowledge bases</b>		
CTD DISEASES	<a href="http://ctdbase.org/downloads/#alldiseases">http://ctdbase.org/downloads/#alldiseases</a>	Copyrighted ◇
CTD CHEMICALS	<a href="https://ctdbase.org/downloads/#allchems">https://ctdbase.org/downloads/#allchems</a>	Copyrighted ◇
NCBI TAXONOMY	<a href="https://www.ncbi.nlm.nih.gov/taxonomy">https://www.ncbi.nlm.nih.gov/taxonomy</a>	Public domain
CELLOSAURUS	<a href="https://www.cellosaurus.org/">https://www.cellosaurus.org/</a>	CC BY 4.0
NCBI GENE	<a href="https://www.ncbi.nlm.nih.gov/gene">https://www.ncbi.nlm.nih.gov/gene</a>	Public domain
DBSNP	<a href="https://www.ncbi.nlm.nih.gov/snp/">https://www.ncbi.nlm.nih.gov/snp/</a>	Public domain
UMLS	<a href="https://www.nlm.nih.gov/research/umls/index.html">https://www.nlm.nih.gov/research/umls/index.html</a>	DUA

**Table 8.** Corpora in BELB with corresponding link and license information. † The original website is no longer available: <https://sites.google.com/site/laurafurlongweb/databases-and-tools/corpora/>. The original corpus is redistributed by (Thomas et al., 2016). ‡ Commercial use is forbidden. ◇ Free for non-commercial uses, otherwise requires paid licensing

offers only a train and a test split, we randomly sample 10% (50 documents) of the training data to be used for development. Both corpora are linked to NCBI GENE (Brown et al., 2015), which integrates detailed information for known and predicted genes, including data from all major taxonomic groups.

**Disease** Standard corpora for disease normalization are NCBI Disease (Doğan et al., 2014) and BC5CDR (Li et al., 2016), originally created for the Chemical Disease Relation (CDR) track at BioCreative V. Entity mentions in these corpora are normalized to CTD DISEASES (Davis et al., 2023), a.k.a. MEDIC, which is a modified subset of descriptors from the “Diseases” branch of MeSH (Lipscomb, 2000), combined with genetic disorders from the OMIM database (Hamosh et al., 2005).

**Chemical** For chemicals we use BC5CDR as it provides as well chemical annotations and additionally include NLM-Chem, a collection of *full text* articles. Specifically we employ the version released for the NLM-Chem track at BioCreative VII (Islamaj et al., 2022). Mentions in these corpora are linked to the chemical branch of MeSH, which however includes broad categories such as “D014867” (“water”). We therefore only retain entity mentions linked to CTD CHEMICALS (Davis et al., 2023), which merges descriptors from the “Chemicals and Drugs” category and Supplementary Concept Records in MeSH and removes several branches of the original MeSH hierarchy if either (i) are not molecular reagents/clinical drugs, e.g. “Purines”, or (ii) are broad chemical classes, e.g. “Poisons”.

**Species** For species normalization, we use the Linnaeus corpus (Martin et al., 2010), a collection of annotated full text articles, and S800 (Pafilis et al., 2013), containing 100 abstracts from 8 different publication categories (e.g. bacteriology). Both corpora are linked to NCBI TAXONOMY (Scott, 2012), the standard nomenclature and classification repository of organisms

for sequences databases such as GenBank. Both corpora do not provide canonical splits. We rely on those defined in <https://github.com/spyysalo/linnaeus-corpus/tree/master/split> and <https://github.com/spyysalo/s800> for Linnaeus and S800 respectively.

**Cell line** To the best of our knowledge, the only available corpus offering normalized entity mentions of cell lines is BioID (Arighi et al., 2017), introduced in the Interactive Bio-ID Assignment Track at BioCreative VI. In contrast to all other corpora, text in BioID are figure captions found in full text articles. The corpus is annotated with mentions of multiple entity types (e.g. chemicals and species), but we retain exclusively those linked to CELLOSAURUS (Bairoch, 2018), a nomenclature of cell lines used in biomedical research. Only the annotated training split was made available for the BioCreative track. We therefore re-structure the training data into 80/10/10 train, development and test split respectively.

**Variant** The de facto standard corpora for variants are: SNP (Thomas et al., 2011), Osiris v1.2 (Furlong et al., 2008) and tmVar v3 (Wei et al., 2022). All corpora contain exclusively a test split. The tmVar (v3) corpus offers multiple normalizations for a given entity mention, e.g. a CAR Canonical Allele Identifier (CA ID) or its corresponding gene. For all corpora, we keep only the entity mentions which are normalized to dbSNP, the primary knowledge base for human genetic variants. Despite its name, dbSNP contains a wide range of polymorphisms besides Short Nucleotide Polymorphisms, e.g. short deletion and insertion polymorphisms and multinucleotide polymorphisms.

**UMLS** For comparison with previous studies we include the MedMentions corpus with the 2017AA full release of UMLS. We note that although CTD DISEASES and CTD CHEMICALS are technically a subset of UMLS, we keep them as separate KBs

because (i) some corpora were specifically linked to them (e.g. NCBI Disease) and (ii) with UMLS containing many unrelated concepts, it would unnecessarily increase the search space.

In Table 8 we report links to all resources included in BELB along with the license with which they are released. All resources created by NLM, as a governmental agency, are by nature of public domain<sup>3</sup>. Many corpora do not specify a license (we mark them as N/A) but can be freely accessed and do not specify any limitation on the data usage (except in forbidding commercial use). The same considerations hold for the knowledge bases. UMLS is the only resource which is not freely available and users are required to enter a Data Usage Agreement (DUA).

## D. MedMentions

	Semantic Group	Entity mentions (%)
1	Phenomena	41,422 (20%)
2	Chemicals & Drugs	37,401 (18%)
3	Procedures	33,478 (16%)
4	Concepts & Ideas	22,824 (11%)
5	Anatomy	22,248 (11%)
6	Living Beings	19,626 (10%)
7	Disorders	18,081 (0.9%)
8	Organizations	2,143 (0.1%)
9	Devices	2,018 (0.1%)
10	Physiology	1,773 (0.1%)
11	Objects	1,352 (0.1%)
12	Occupations	9,16 (0%)
13	Activities & Behaviors	0 (0%)
14	Genes & Molecular Sequences	0 (0%)
15	Geographic Areas	0 (0%)

**Table 9.** Ranked number of entity mentions (and relative amount) in MedMentions (ST21PV) grouped by UMLS Semantic Groups.

In Table 9 we report the ranked number of entity mentions in MEDMENTIONS (ST21PV) grouped by their UMLS Semantic Groups<sup>4</sup>. As reported in Section 2.1.1 entity types such as diseases (“Disorders”) and species (“Living Beings”) are covered only marginally, while genes (“Genes & Molecular Sequences”) are completely absent. Notably, a high proportion of mentions (~47%) is devoted instead to general entities such as “Phenomena” and “Procedures”.

## E. Unified schema for knowledge bases

In Listing 2 we provide an overview of the unified schema used to store all knowledge bases in BELB. In its basic form, a KB is a list of synonyms (names), each associated with a single entity. All KBs provide as well information about each name (“description”). For instance in NCBI TAXONOMY a name can be the “scientific

name” of a species (“Homo Sapiens”) or the “common” one (“human”). In all KBs exclusively one name must be the primary one, i.e. the one most commonly used to refer to the concept represented by the entity. For instance, the primary name (a.k.a symbol) for entity “2” in NCBI GENE is “A2M”. Some of the KBs are interconnected. For instance, “ $\alpha$ 2microglobulin” represents a different entity when referring to the human or rat gene. Thus, besides having different identifiers (“2” and “24153” respectively), to ease downstream applications (e.g. data integration), NCBI GENE provides what we call (borrowing from the database jargon) a *foreign* entity. For instance, all entries in NCBI Gene with identifier 2 are accompanied by the foreign entity “9606”, i.e. the entity in NCBI TAXONOMY denoting “Homo Sapiens” (human). If available, a KB provides as well a *history* table, where changes to the identifiers are tracked, i.e. if they have been replaced by others or have become obsolete.

## F. Updated corpora

	Entities		
	Replaced	Removed	Total
GNormPlus	-	1	1 (0.03%)
NLM-Gene	1	1	2 (0.07%)
NCBI Disease	-	11	11 (0.25%)
BC5CDR (C)	-	243	243 (4.56%)
NLM-Chem	-	36	36 (0.31%)
Linnaeus	51	-	51 (3.57%)
S800	2	-	2 (0.26%)
BioID	-	-	0 (0.0%)
SNP	6	5	11 (2.13%)
Osiris v1.2	7	-	7 (2.68%)
tmVar v3	5	-	5 (0.49%)
MedMentions	-	-	0 (0.0%)

**Table 10.** Overview of the number of changes in entity labels in the test split of each corpus in BELB.

In Table 10 we report the number of changes in entity label in the test split of each BELB corpus. For each gold label associated to an entity mention there can be two types of changes. Either the label has been replaced (Replaced), and in this case it can be updated, or it was removed from the KB (Removed), which makes the label obsolete and the mention not linkable, in which case we exclude the entity mention from the test set.

## G. Biomedical entity linking systems

In Table 11 we report all systems (and the link to their original implementation) taken into consideration in our benchmarking.

### G.1. Rule-based entity-specific systems

In Table 12 we provide an overview of the rule-based entity-specific models. Implementation details for each model are reported below.

**GNormPlus** uses a CRF Model to perform entity recognition. The normalization component is a statistical inference network based on TF-IDF frequencies. The system comes with two pre-trained models, namely: “GNR.Model”, which was trained on the train and development split (as defined by BELB) of GNormPlus and “GNR.GNormPlusCorpus\_NLMGeneTrain.Model”, which was trained on the whole

<sup>3</sup> See <https://www.ncbi.nlm.nih.gov/CBBresearch/Dogan/DISEASE/disclaimer.html> for the public domain notice which usually accompanies these resources.

<sup>4</sup> <https://lhncbc.nlm.nih.gov/ii/tools/MetaMap/documentation/SemanticTypesAndGroups.html>

**Listing 2** Example SQL code defining the BELB schema for all knowledge bases.

```

CREATE TABLE kb(
  uid INTEGER PRIMARY KEY,
  entity INTEGER NOT NULL,
  description INTEGER NOT NULL,
  name TEXT NOT NULL,
  foreign_entity INTEGER REFERENCES foreign_entities(entity),
)

CREATE TABLE foreign_entities(
  entity INTEGER NOT NULL,
  name TEXT NOT NULL,
)

CREATE TABLE history(
  old INTEGER PRIMARY KEY,
  new INTEGER NOT NULL,
)

```

	Implementation (link)
<b>Rule-based entity-specific</b>	
GNormPlus	<a href="https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/gnormplus/">https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/gnormplus/</a>
TaggerOne	<a href="https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/taggerone/">https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/taggerone/</a>
tmVar v3	<a href="https://ftp.ncbi.nlm.nih.gov/pub/lu/tmVar3/">https://ftp.ncbi.nlm.nih.gov/pub/lu/tmVar3/</a>
BC7T2	<a href="https://github.com/bioinformatics-ua/biocreativeVII_track2">https://github.com/bioinformatics-ua/biocreativeVII_track2</a>
SR4GN	<a href="https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/sr4gn/">https://www.ncbi.nlm.nih.gov/research/bionlp/Tools/sr4gn/</a>
FuzzySearch	<a href="https://github.com/maxbachmann/RapidFuzz">https://github.com/maxbachmann/RapidFuzz</a>
<b>Pre-trained language model</b>	
arboEL	<a href="https://github.com/dhdhagar/arboEL">https://github.com/dhdhagar/arboEL</a>
GenBioEl	<a href="https://github.com/Yuanhy1997/GenBioEL">https://github.com/Yuanhy1997/GenBioEL</a>
BioSyn	<a href="https://github.com/dmis-lab/BioSyn">https://github.com/dmis-lab/BioSyn</a>

**Table 11.** Overview of the biomedical entity linking systems benchmarked on BELB.

	Entity type(s)	Recognition	Linking
GNormPlus	Gene	CRF	Inference Network + TF-IDF + Rules
TaggerOne	Disease, Cell line	semi-Markov model	TF-IDF
BC7T2W	Chemical	-	String matching + Embeddings
SR4GN	Species	String matching	String matching + Rules
tmVar	Variant	String matching	String matching + Rules
SciSpacy	UMLS	-	TF-IDF
FuzzySearch	-	-	Levenshtein Distance

**Table 12.** Overview of the rule-based entity-specific baselines benchmarked on BELB.

**GNormPlus** corpus and the train and development split (as defined by BELB) of the **NLM-Gene** corpus. We use the first one when evaluating on **GNormPlus** and the second on **NLM-Gene**.

**SR4GN** (Species Recognition for Gene Recognition) is a rule-based system which, as the name suggests, is mainly a support component for gene normalization. It implements several custom rules to address cases where species information is not explicitly available. We run **GNormPlus** as well on the species corpora as **SR4GN** is only available as a **GNormPlus** component.

**tmVar** uses pattern matching to both recognize and normalize variants, falling back to dictionary-lookup when the first fails. It is distributed with a pre-trained model and a pre-processed

version of **dbSNP**. Its usage depends on **GNormPlus**, as it requires normalized gene mentions to perform linking.

**TaggerOne** is a general purpose joint recognition and linking system based on a semi-Markov model. It provides two models: “model\_NCBID.bin” and “model\_BC5CDRD.bin” which are trained on the train split of **NCBI Disease** and the disease annotations of **BC5CDR** respectively. [Wei et al. \(2019\)](#) reports to use a **TaggerOne** model trained on **BioID**. They however do not publicly release the trained model. Our attempt to use **TaggerOne** training code resulted in an error.

**BC7T2W** is a hybrid model based on dictionary-lookup and **BioBERT** embeddings ([Lee et al., 2020](#)). By default the systems

includes in the target KB all mentions in NLM-Chem with their gold labels. We modify the “settings.yaml” file to disable this option.

**SciSpacy** comes with a joint entity recognition and linking pipeline. However, it is possible to run only the linking component using the abbreviation detection module separately (we use the one integrated in the “en\_core\_sci\_sm” model<sup>5</sup>) and feeding the result to linking system (“scispacy\_linker”).

**FuzzySearch** This approach assigns a score in  $[0, 1]$  to pairs of strings. The score is defined as  $\frac{D}{|s_i|+|s_j|}$ , where  $D$  is the edit distance between strings  $s_i$  and  $s_j$  and  $|s_i|$  is the number of characters in  $s_i$ . We use the implementation provided by <https://github.com/maxbachmann/RapidFuzz>. Given a test mention we compute the similarity score with all synonyms in a KB and select the one with the highest score.

## G.2. Pre-trained language models

We convert all corpora and KBs in BELB in the format required by each model and re-train them with the default hyper-parameters reported by the original implementations. All models are trained and evaluated using two Nvidia Tesla A100.

**BioSyn** We use the default hyper-parameters provided by the authors. Unlike the original approach, we exclusively train on the train split of corpora. The backbone pre-trained language model is BioBERT.

**GenBioEl** is initialized with BART (“large”) weights (Lewis et al., 2020). It uses different values for learning rate and warmup steps for NCBI Disease and BC5CDR. We cannot perform a full hyper-parameter search for each corpus, and therefore select the values that work best for both corpora, i.e. a learning reate of  $1e-5$  and 500 warmup steps.

**arboEL** is initialized with BioBERT. The inference procedure for arboEL is parametrized by the number of  $k$  nearest neighbor used to construct the graph (determining which pairs of nodes are connected). The implementation provided by the authors runs the inference trying different  $k \in \{0, 1, 2, 4, 8\}$ . For fair comparison with other models, we do not perform any hyperparameter optimization and hence report the score for  $k = 0$ .

## H. Additional results

	Corpora			
GNormPlus	GNormPlus	NLM-Gene		
	0.93	0.73		
SR4GN	Linnaeus	S800		
	0.80	0.70		
TaggerOne	NCBI Disease	BC5CDR (D)		
	0.82	0.82		
tmVar	SNP	Osiris v1.2	tmVar v3	
	0.91	0.67	0.92	

**Table 13.** NER recall of rule-based entity-specific systems which perform joint recognition and normalization.

	RBES	BioSyn	GenBioEl	arboEL
<b>Disease</b>	0.94	0.84	0.89	0.87
NCBI Disease	0.94	0.82	0.87	0.86
BC5CDR (D)	0.94	0.87	0.92	0.88
<b>Chemical</b>	0.72	0.72	0.81	0.77
BC5CDR (C)	0.82	0.85	0.95	0.88
NLM-Chem	0.67	0.67	0.75	0.72
<b>Cell line</b>				
BioID	0.80	0.81	0.95	0.95
<b>Species</b>	0.97	0.91	0.85	0.76
Linnaeus	0.99	0.93	0.81	0.74
S800	0.93	0.88	0.93	0.79
<b>Gene</b>	0.81	-	0.05	0.30
GNormPlus	0.86	OOM	0.06	0.36
NLM-Gene	0.75	OOM	0.03	0.23
<b>Variant</b>	0.90			
SNP	0.94	-	-	-
Osiris v1.2	0.91	-	-	-
tmVar v3	0.88	-	-	-
<b>UMLS</b>				
MedMentions	0.58	OOM	0.41	0.69

**Table 14.** Performance of all baselines on BELB (test set) with strict evaluation (see Section 2.3.1). All scores are *mention-level recall@1*. OOM: out-of-memory (>200GB)

	RBES	BioSyn	GenBioEL	arboEL
<b>Disease</b>		0.84	0.88	0.84
NCBI Disease	-	0.81	0.84	0.80
BC5CDR (D)	-	0.85	0.89	0.85
<b>Chemical</b>	0.72	0.72	0.81	0.77
BC5CDR (C)	0.82	0.85	0.95	0.87
NLM-Chem	0.67	0.67	0.75	0.72
<b>Cell line</b>				
BioID	0.82	0.82	0.96	0.95
<b>Species</b>		0.87	0.81	0.76
Linnaeus	-	0.89	0.77	0.75
S800	-	0.83	0.89	0.79
<b>Gene</b>		-	0.18	0.28
GNormPlus	-	OOM	0.20	0.35
NLM-Gene	-	OOM	0.10	0.21
<b>Variant</b>				
SNP	-	-	-	-
Osiris v1.2	-	-	-	-
tmVar v3	-	-	-	-
<b>UMLS</b>				
MedMentions	0.58	OOM	0.57	0.69

**Table 15.** Performance of all baselines on the full test set of all BELB corpora (see Section 2.3.2). All scores are *mention-level recall@1*. OOM: out-of-memory (>200GB)

<sup>5</sup> [https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/releases/v0.5.1/en\\_core\\_sci\\_sm-0.5.1.tar.gz](https://s3-us-west-2.amazonaws.com/ai2-s2-scispacy/releases/v0.5.1/en_core_sci_sm-0.5.1.tar.gz)